Kairos Pharma's Upcoming Fireside Chat at the Virtual Summit
Kairos Pharma Ltd. (NYSE: KAPA) is generating excitement as it announces significant participation in a renowned healthcare summit. The company is set to have its Chief Executive Officer, John S. Yu, M.D., engage in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. During this event, Dr. Yu will engage in meaningful discussions with Jason McCarthy, Ph.D., who is the Senior Managing Director and Head of Biotechnology Research at Maxim Group.
Engagement Highlights from the Virtual Summit
The virtual summit is a prestigious platform that will take place over three days, providing a unique opportunity for industry leaders to share insights into the latest developments in the biopharmaceutical field. As the healthcare landscape constantly evolves, such discussions allow for the sharing of innovative ideas and key industry trends.
About the Event
The fireside chat, which is one of the focal points of the summit, is scheduled for October 17, 2024, at 1:00 PM ET. This event will not only highlight Kairos Pharma's ongoing initiatives but also foster connections within the biotechnology community.
Kairos Pharma’s Mission in Oncology
With a commitment to transforming cancer treatment, Kairos Pharma is at the forefront of oncology therapeutics. The company utilizes advanced structural biology techniques to tackle drug resistance and immune suppression that affect cancer treatments. Their lead candidate, ENV105, targets CD105, a protein linked to drug resistance, aiming to enhance the effectiveness of standard treatment protocols.
Current Clinical Trials
Currently, ENV105 is making strides in clinical trials, specifically in Phase 2 for prostate cancer and Phase 1 for lung cancer. These trials are critical as they address substantial unmet medical needs in oncology, showcasing Kairos Pharma's dedication to improving patient outcomes.
Future Prospects and Innovations
The biotechnology sector remains dynamic, and Kairos Pharma's proactive approach in the clinical stages reflects their innovative spirit. As they prepare for discussions at the summit, the insights shared by Dr. Yu promise to shed light on the company's future strategies and the potential impacts on cancer therapy.
Continued Commitment to Advancement
As the healthcare industry continues to push boundaries, Kairos Pharma stands prepared to contribute significantly. The forthcoming fireside chat at the Maxim Healthcare Virtual Summit is an excellent avenue for the company to articulate its vision and innovative approaches in oncology.
Frequently Asked Questions
What is Kairos Pharma Ltd. known for?
Kairos Pharma Ltd. focuses on developing therapies that target cancer drug resistance, particularly through their candidate ENV105, which targets CD105.
When is the fireside chat taking place?
The fireside chat is scheduled for October 17, 2024, at 1:00 PM ET during the Maxim Healthcare Virtual Summit.
Who will be participating in the chat?
John S. Yu, M.D., the CEO of Kairos Pharma, will participate in the chat alongside Jason McCarthy, Ph.D., a senior managing director at Maxim Group.
What is the significance of the CD105 protein?
CD105 is associated with drug resistance in cancer therapies, and targeting it could enhance the efficacy of existing treatment options.
How can I learn more about Kairos Pharma's trials?
Detailed information about their clinical trials and progress can be found on their official website, kairospharma.com.